Yong Zhang1,2, Tingkun Wu1, Jingjing Xie1, Liqun Yan1, Xiuli Guo1, Weijia Xu1, Liping Wang3,4. 1. Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, People's Republic of China. 2. Division of Nephrology, The 900th Hospital of Joint Logistic Support Force, PLA, 156 West Second Ring Road, Fuzhou, 350025, People's Republic of China. 3. Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, People's Republic of China. wlp03291122@126.com. 4. Division of Nephrology, The 900th Hospital of Joint Logistic Support Force, PLA, 156 West Second Ring Road, Fuzhou, 350025, People's Republic of China. wlp03291122@126.com.
Abstract
PURPOSE: Nephrectomy, partial or radical, remains the standard treatment for renal cell carcinoma (RCC). However, increased risk of chronic kidney disease (CKD) must still be considered. This study aimed to evaluate the effects of concomitant metabolic syndrome (MetS) on renal function in patients with RCC after radical nephrectomy. METHODS: Medical records of 310 patients who underwent radical nephrectomy for clear-cell RCC at 900th Hospital of the Joint Logistics Support Force, PLA from December 2012 to January 2017 were reviewed retrospectively. Estimated glomerular filtration rate (eGFR) and CKD stages were calculated at one week preoperative as baseline and then at postoperative 1 week, 3 months, 12 months and 24 months. MetS patients were identified and enrolled in the MetS group (n = 31), and a non-MetS group was selected by propensity score matching (n = 31). Non-neoplastic renal parenchyma specimens taken at least 2 cm from edge of tumor were evaluated. RESULTS: Baseline characteristics between the two groups were comparable. At 24 months postoperative, mean eGFR levels of the MetS group were significantly lower than those in the non-MetS group (62.7 vs. 73.3 ml/min/1.73 m2; p = 0.004). CKD stages were still more severe in the MetS group than those in the non-MetS group (p = 0.006). The proportions of global sclerosis, tubular atrophy and interstitial fibrosis were all significantly more prevalent in MetS patients, compared to non-MetS patients (all p < 0.05). CONCLUSION: In RCC patients with MetS, the possibility of declining eGFR and CKD progression must be considered after radical nephrectomy. Routine monitoring of renal function must be emphasized.
PURPOSE: Nephrectomy, partial or radical, remains the standard treatment for renal cell carcinoma (RCC). However, increased risk of chronic kidney disease (CKD) must still be considered. This study aimed to evaluate the effects of concomitant metabolic syndrome (MetS) on renal function in patients with RCC after radical nephrectomy. METHODS: Medical records of 310 patients who underwent radical nephrectomy for clear-cell RCC at 900th Hospital of the Joint Logistics Support Force, PLA from December 2012 to January 2017 were reviewed retrospectively. Estimated glomerular filtration rate (eGFR) and CKD stages were calculated at one week preoperative as baseline and then at postoperative 1 week, 3 months, 12 months and 24 months. MetS patients were identified and enrolled in the MetS group (n = 31), and a non-MetS group was selected by propensity score matching (n = 31). Non-neoplastic renal parenchyma specimens taken at least 2 cm from edge of tumor were evaluated. RESULTS: Baseline characteristics between the two groups were comparable. At 24 months postoperative, mean eGFR levels of the MetS group were significantly lower than those in the non-MetS group (62.7 vs. 73.3 ml/min/1.73 m2; p = 0.004). CKD stages were still more severe in the MetS group than those in the non-MetS group (p = 0.006). The proportions of global sclerosis, tubular atrophy and interstitial fibrosis were all significantly more prevalent in MetS patients, compared to non-MetS patients (all p < 0.05). CONCLUSION: In RCC patients with MetS, the possibility of declining eGFR and CKD progression must be considered after radical nephrectomy. Routine monitoring of renal function must be emphasized.
Authors: Börje Ljungberg; Laurance Albiges; Yasmin Abu-Ghanem; Karim Bensalah; Saeed Dabestani; Sergio Fernández-Pello; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Teele Kuusk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Thomas Powles; Michael Staehler; Rana Tahbaz; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2019-02-23 Impact factor: 20.096
Authors: Robert J Ellis; Victoria M White; Damien M Bolton; Michael D Coory; Ian D Davis; Ross S Francis; Graham G Giles; Glenda C Gobe; David J T Marco; Rachel E Neale; Simon T Wood; Susan J Jordan Journal: Clin Genitourin Cancer Date: 2019-03-15 Impact factor: 2.872
Authors: John T Leppert; Remy W Lamberts; I-Chun Thomas; Benjamin I Chung; Geoffrey A Sonn; Eila C Skinner; Todd H Wagner; Glenn M Chertow; James D Brooks Journal: J Am Soc Nephrol Date: 2017-10-10 Impact factor: 10.121
Authors: Brian R Lane; Sevag Demirjian; Ithaar H Derweesh; Toshio Takagi; Zhiling Zhang; Lily Velet; Cesar E Ercole; Amr F Fergany; Steven C Campbell Journal: Eur Urol Date: 2015-05-23 Impact factor: 20.096
Authors: S Z Liu; L W Guo; X Q Cao; Q Chen; S K Zhang; M Zhang; D Yu; P L Quan; X B Sun; W Q Chen Journal: Zhonghua Liu Xing Bing Xue Za Zhi Date: 2018-10-10
Authors: Robert J Ellis; Sharon J Del Vecchio; Kevin M J Gallagher; Danielle N Aliano; Neil Barber; Damien M Bolton; Etienne T S Chew; Jeff S Coombes; Michael D Coory; Ian D Davis; James F Donaldson; Ross S Francis; Graham G Giles; Glenda C Gobe; Carmel M Hawley; David W Johnson; Alexander Laird; Steve Leung; Manar Malki; David J T Marco; Alan S McNeill; Rachel E Neale; Keng L Ng; Simon Phipps; Grant D Stewart; Victoria M White; Simon T Wood; Susan J Jordan Journal: J Am Soc Nephrol Date: 2020-04-01 Impact factor: 10.121